Factors associated with PNR to CD19 CAR T cells
| Risk factor . | Response rates . |
|---|---|
| Prior blinatumomab | 64.5% in blinatumomab nonresponders vs 92.9% in blinatumomab responders vs 93.5% in blinatumomab-untreated patients6 |
| Bone marrow disease burden | 73% in HB (>5% blasts) vs 98% in low disease burden vs 100% in undetectable7 |
| Cytogenetics | 93% in high risk vs 86% in intermediate risk vs 98% in favorable risk9 |
| Apheresed peripheral blood T cells | 28.6% when CD8 cells express LAG3 ≥0.745% AND TNF-α <25.283% vs 100% for all others10 |
| CD19 isoforms | The presence of increased transcripts with CD19 isoforms skipping exon 2 yield nonresponse1,11 |
| Bone marrow epigenetics | Hypermethylation at genes known to be targets of PRC2 repression in embryonic stem cells yields nonresponse1 |
| Risk factor . | Response rates . |
|---|---|
| Prior blinatumomab | 64.5% in blinatumomab nonresponders vs 92.9% in blinatumomab responders vs 93.5% in blinatumomab-untreated patients6 |
| Bone marrow disease burden | 73% in HB (>5% blasts) vs 98% in low disease burden vs 100% in undetectable7 |
| Cytogenetics | 93% in high risk vs 86% in intermediate risk vs 98% in favorable risk9 |
| Apheresed peripheral blood T cells | 28.6% when CD8 cells express LAG3 ≥0.745% AND TNF-α <25.283% vs 100% for all others10 |
| CD19 isoforms | The presence of increased transcripts with CD19 isoforms skipping exon 2 yield nonresponse1,11 |
| Bone marrow epigenetics | Hypermethylation at genes known to be targets of PRC2 repression in embryonic stem cells yields nonresponse1 |
TNF-α, tumor necrosis factor α.